EXPLORE!

Clinical news

EMA Approves Dasiglucagon for Severe Hypoglycemia Management in Diabet...

21 November 2024  

The European Medicines Agency (EMA) has granted approval for dasiglucagon in 2024, providing a new therapeutic option for the treatment of severe hypoglycemia in diabetes patients. Dasiglucagon, a novel rescue therapy, is formulated to rapidly elevate blood glucose levels during severe hypoglycemic episodes, which can lead to confusion, seizures, unconsciousness, and, in extreme cases, death if n.. MORE

US FDA Approved Alectinib as Adjuvant Treatment for ALK-positive NSCLC

20 November 2024  

Alectinib has indeed been approved by the US FDA for use as adjuvant treatment in patients with ALK-positive non-small cell lung cancer (NSCLC) following tumor resection... MORE

FDA Approves Revumenib for High-Risk Acute Leukemia

19 November 2024  

The FDA has approved revumenib (Revuforj) for treating relapsed or refractory acute leukemia with KMT2A translocation in patients aged 1 year andolder. This menin inhibitor, developed by Syndax Pharmaceuticals, offers atargeted therapy option for this high-risk leukemia subtype... MORE

FDA Approves Revumenib for Acute Leukemia

18 November 2024  

The FDA has approved revumenib for relapsedor refractory acute leukemia with a KMT2A translocation in patientsaged 1 year and older, offering a targeted therapy for this geneticsubtype... MORE

FDA Approves First Treatment for Severe Frostbite: Iloprost Injection

16 November 2024  

TheU.S. Food and Drug Administration (FDA) has approved Iloprost injectionas the first treatment specifically for severe frostbite. Marketed under thename Aurlumyn, iloprost is a vasodilator that helps prevent clotting andreduces the risk of finger or toe amputation in adults with severe frostbite... MORE

FDA Approves Imetelstat for Transfusion-Dependent Anemia in MDS

16 November 2024  

The FDA has approved imetelstat for adultswith low- to intermediate-1 risk myelodysplastic syndromes (MDS) andtransfusion-dependent anemia requiring ≥4 red blood cell units over 8 weeks. Itis indicated for patients unresponsive, resistant, or ineligible for erythropoiesis-stimulatingagents (ESAs). Imetelstat, a telomerase inhibitor, addresses a c.. MORE

FDA Approves First NASH Treatment for Liver Scarring

15 November 2024  

The FDA has approved Rezdiffra for adultswith noncirrhotic non-alcoholic steatohepatitis (NASH) and moderate to advancedliver scarring, to be used alongside diet and exercise... MORE


eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.